Anti-cancer drug could improve symptoms after stroke
A study by the Institut de Neurociències of the UAB (INc-UAB) demonstrates in animal models the benefits of vorinostat after having suffered a stroke. The drug, used in humans to treat cutaneous T-cell lymphoma, has been proved to mitigate brain injuries and help in restoring brain tissue.
Ischemic stroke is the second leading cause of death worldwide and occurs when blood flow cannot reach the brain due to an obstruction. (Source: World Pharma News)
Source: World Pharma News - February 28, 2024 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
Citius Pharmaceuticals Resubmits the Biologics License Application of Lymphir (denileukin diftitox) for the Treatment of Adults With Relapsed or Refractory Cutaneous T-Cell Lymphoma
CRANFORD, N.J., Feb. 13, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ( " Citius " or the " Company " ) (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - February 13, 2024 Category: Drugs & Pharmacology Source Type: news
Dupilumab-Associated Lymphoid Reactions Require Caution Dupilumab-Associated Lymphoid Reactions Require Caution
Retrospective study identifies potential for misdiagnosed mycosis fungoides and for dupilumab to fuel cutaneous lymphoid reactions that mimic mycosis fungoides in patients with atopic dermatitis.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - October 30, 2023 Category: Allergy & Immunology Tags: Dermatology News Source Type: news
Lymphoid Reaction Observed in Eczema Patients Receiving Dupilumab
MONDAY, Oct. 30, 2023 -- For adults with atopic dermatitis (AD) receiving dupilumab treatment, a reversible lymphoid reaction (LR) has been observed, which mimics cutaneous T-cell lymphoma (CTCL), according to a study published online Oct. 18 in... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 30, 2023 Category: Pharmaceuticals Source Type: news
Chlormethine Gel for the Treatment of Mycosis Fungoides Chlormethine Gel for the Treatment of Mycosis Fungoides
Review the use of chlormethine gel, a topical antineoplastic agent, for the treatment of stage IA and IB mycosis fungoides-cutaneous T-cell lymphoma.Skin Therapy Letter (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 3, 2023 Category: Consumer Health News Tags: Dermatology Journal Article Source Type: news
Allo-Transplant Tied to Better PFS in Advanced Cutaneous T-Cell Lymphomas
(MedPage Today) -- Allogeneic hematopoietic stem cell transplantation (HSCT) was associated with significant improvements in progression-free survival (PFS) in patients with advanced cutaneous T-cell lymphomas (CTCLs), according to the propensity... (Source: MedPage Today Dermatology)
Source: MedPage Today Dermatology - May 11, 2023 Category: Dermatology Source Type: news
Soligenix Announces Positive Clinical Results from Compatibility Study of HyBryte(TM) in the Treatment of Cutaneous T-Cell Lymphoma
Results Confirm and Extend Response Results from Phase 3 FLASH Study
PRINCETON, N.J., May 4, 2023 -- (Healthcare Sales & Marketing Network) -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on ... Biopharmaceuticals, Oncology Soligenix, HyBryte, synthetic hypericin, photodynamic therapy, CTCL (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - May 4, 2023 Category: Pharmaceuticals Source Type: news
Soligenix Provides Regulatory Update on HyBryte(TM)
PRINCETON, N.J., April 14, 2023 -- (Healthcare Sales & Marketing Network) -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where ... Biopharmaceuticals, Oncology, FDA Soligenix, HyBryte, synthetic hypericin sodium, CTCL (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - April 14, 2023 Category: Pharmaceuticals Source Type: news
Soligenix Receives Refusal to File Letter from U.S. FDA for HyBryte(TM) New Drug Application in the Treatment of Cutaneous T-Cell Lymphoma
Soligenix intends to seek guidance from the FDA on how to further advance HyBryte towards potential approval
PRINCETON, N.J., Feb. 14, 2023 -- (Healthcare Sales & Marketing Network) -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-... Biopharmaceuticals, Oncology, FDA Soligenix, HyBryte, synthetic hypericin, photodynamic therapy, CTCL (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 14, 2023 Category: Pharmaceuticals Source Type: news
Extracorporeal Photopheresis and Its Use in Dermatology Extracorporeal Photopheresis and Its Use in Dermatology
While cutaneous T-cell lymphoma remains the only FDA approved use of extracorporeal photopheresis, it has potential as an off-label treatment for numerous dermatological conditions.Skin Therapy Letter (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 18, 2023 Category: Consumer Health News Tags: Dermatology Journal Article Source Type: news
New PDT Therapy for CTCL to Be Reviewed by FDA New PDT Therapy for CTCL to Be Reviewed by FDA
The treatment employs an ointment formulation of synthetic hypericin that is preferentially absorbed into malignant cells and activated with visible light, rather than ultraviolet light.MDedge News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 22, 2022 Category: Cancer & Oncology Tags: Dermatology News Source Type: news
Pandemic Delayed Treatment in Patients With CTCL, Study Finds Pandemic Delayed Treatment in Patients With CTCL, Study Finds
The retrospective study analyzed data on 149 patients with CTCL who were being managed at one of nine international academic medical centers in seven countries from March through October 2020.MDedge News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 5, 2022 Category: Cancer & Oncology Tags: Dermatology News Source Type: news
Incidence of Cutaneous T - Cell Lymphoma Up in the U.S.
Overall incidence rate six times higher for patients aged 40 years or older versus younger than 40 years, but increase in CTCL rate significantly higher for those younger than 40 years (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - September 13, 2022 Category: Cancer & Oncology Tags: Internal Medicine, Oncology, Pathology, Journal, Source Type: news
Incidence of Cutaneous T-Cell Lymphoma Up in the U.S.
TUESDAY, Sept. 13, 2022 -- The overall incidence of cutaneous T-cell lymphoma (CTCL) increased in the United States from 2000 to 2018, according to a research letter published online Sept. 1 in JAMA Oncology.
Zhuo Ran Cai, M.D., from Stanford... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 13, 2022 Category: Pharmaceuticals Source Type: news
Michael Girardi appointed Evans Professor of Dermatology
Girardi is an internationally recognized investigator and translational expert in the advancement of personalized therapy for cutaneous T cell lymphoma. (Source: Yale Science and Health News)
Source: Yale Science and Health News - June 21, 2022 Category: Universities & Medical Training Source Type: news
